Some of the less investigated mechanisms to BCR::ABL1 TKI resistance are epigenetic changes such as HOXA4 promoter hypermethylation, which could lead to IM resistance in CML patients. This evidence concerns the gene HOXA4 and chronic myelogenous leukemia, BCR-ABL1 positive.